samedan logo
 
 
 
spacer
home > ebr > spring 2017 > express yourself
PUBLICATIONS
European Biopharmaceutical Review

Express Yourself

EBR: Oxford Genetics offers numerous services in preclinical R&D. Can you tell us a little about some of these?

Paul Brooks: Oxford Genetics is a synthetic biology company that offers products and services to support the discovery, development and production of biologics, gene and cell therapies. We have tremendous expertise in designing DNA, optimising expression of proteins, improving viral delivery systems and cell line development.

In your opinion, what is the significance of the research undertaken at Oxford Genetics for the wider patient base, and how does it contribute to the production of new and efficacious vaccines?

Oxford Genetics is addressing some of the fundamental problems affecting the biopharmaceutical industry in relation to maximising productivity. We are helping to achieve cost-effective production of material for clinical testing and commercial manufacture from smaller batch sizes, which offers a viable route to market for therapies that might not otherwise make it.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Ryan Cawood is Chief Executive Officer and founder of Oxford Genetics. He established the company in 2011 with the aim to revolutionise DNA design, optimisation and assembly in order to enable molecular engineering to fulfil its promise in synthetic biology and medicine. Ryan’s research interests include vaccines and treatments for infectious diseases and cancer. He was inspired to create Oxford Genetics after observing that inefficient DNA design and assembly often limit scientific progress. Ryan has a degree in Genetics and a PhD from Oxford University, UK.

Paul Brooks is Commercial Director at Oxford Genetics. He recently joined the company from Sigma-Aldrich, where he was responsible for the commercialisation of their functional genomic technologies – including those for genome-editing. Over the course of his career, Paul has held various senior management positions in both the US and Europe, and has overseen the development, marketing and sales of genomic technologies, products and services. He holds a PhD in Molecular Biology from the University of Manchester, UK, and an MBA from the University of Nottingham, UK.
spacer
Ryan Cawood
spacer
spacer
spacer
Paul Brooks
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

FUJIFILM Irvine Scientific Begins Customer Qualification of European Manufacturing Facility

SANTA ANA, California, September 29, 2021: FUJIFILM Irvine Scientific, Inc., today announced that it completed construction and started the commissioning phase of its new manufacturing facility in Tilburg, the Netherlands. The commissioning milestone marks the beginning of validating the facility and equipment in anticipation of full operations starting in late 2021.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement